Posted by Michael Wonder on 02 Mar 2025
Teva and Medincell announce FDA acceptance of supplemental new drug application for Uzedy (risperidone) extended release injectable suspension as a treatment for patients with bipolar I disorder
25 February 2025 - Uzedy is currently approved in the US as a subcutaneous long-acting injectable for use every one or two months for the treatment of schizophrenia in adults.
Teva Pharmaceuticals and Medincell announced today that the supplemental new drug application for Uzedy extended release injectable suspension for the maintenance treatment of bipolar 1 disorder in adults has been accepted for filing by the US FDA.
